Enhancer reprogramming which promotes phenotypic plasticity and endocrine therapy resistance in breast cancer has also been observed to be mediated by the coordinated role of GATA3 and AP1 TFs which re-organize enhancer landscape promoting tumor phenotypic plasticity (72). Here, GATA3 is linked to breast carcinoma.